To improve the health and quality of life of cancer patients.
 
   CIPREVO aims to be a player in Oncology, focused on the development of innovative drug candidates from your laboratories and from our laboratory.
 
   Two pillars support our strategy:
1/ Working with you on your R&D projects as expertise provider
2/ Developing our own portfolio of drug candidates based on our experimental drug discovery platform.


 
   Meet the best partners to speed up your R&D projects against cancer and take benefit of their expertise to increase the values of your own programs.
 
   Despite much progress in disease management, cancer is still one of the leading causes of mortality in the world. Innovations and solutions are covering many complementary aspects including prevention, early detection, personalized medicine, new treatments, patient involvement as well as continuous education for researchers and medical staffs.
 
   In this context, CIPREVO is acting as an expertise provider with its unique network of worldwide experts and helps you to identify, meet and work with the best partners from the different sectors such as health industry, scientific communities, anticancer medical centers, finances and the education.
​​
   CIPREVO has been created in 2013 by Dr Grégoire PREVOST as a private company based in France. Clients may have the benefit of the French research tax credit and the financial support from MEDICEN and BPI France and university innovation center (PUI).